MSF Access @msfaccess.org · 24/09/2026Publicly available information on pricing, licensing, supply, and post-trial access remains very limited despite repeated calls for transparency. 111
MSF Access @msfaccess.org · 29/07/2026We are taking our demand directly to Gilead at the #AIDS2026 conference in Rio de Janeiro, Brazil - a country where people still can't access lenacapavir, even when they contributed to the clinical trials for this breakthrough HIV drug. Read more: www.instagram.com/p/DbThjxUH4gy/ 164
MSF Access @msfaccess.org · 19/06/2026This Ebola disease outbreak once again exposes persistent failures to ensure that accessible medical tools for diseases disproportionately affecting low- and middle-income countries are prioritised, funded, and produced as part of R&D. It has to change now. msfaccess.org/principles-e... 021
MSF Access @msfaccess.org · 08/06/2026With no validated treatments or vaccines yet, and limited diagnostics for Bundibugyo virus disease, R&D and funding must embed transparent and enforceable conditions from the outset to guarantee timely, sustainable access to affordable medical tools for the most affected communities. 110
MSF Access @msfaccess.org · 27/05/2026“A more equitable system can begin today if governments choose to act on the commitments they have already made in the Pandemic Agreement.” MSF statement at #WHA79, delivered by Yuanqiong Hu, Head of Analysis, MSF Access. Read the full statement: msfaccess.org/open-ended-i... 010
MSF Access @msfaccess.org · 21/05/2026This week, we're right here at the World Health Assembly #WHA79, calling for countries to make sure global health policies for the coming years ensure everyone, everywhere has access to affordable medical products. 132
MSF Access @msfaccess.org · 18/05/2026📌Ensuring flexible and adapted delivery models to reach children in conflict settings and stop delays in people’s access to lifesaving vaccines. 100
MSF Access @msfaccess.org · 18/05/2026📌Removing administrative and bureaucratic blockages and strengthening collaboration between health authorities, humanitarian partners, and communities to ensure timely and unhindered access to vaccine supplies and hard-to-reach areas. 100
MSF Access @msfaccess.org · 30/04/2026In 2024, half of the 14.3 million children who missed out on receiving any vaccination lived in countries affected by conflict, fragility, or humanitarian crises. It's time to close this gap through timely access to vaccines for all children, everywhere. #WorldImmunizationWeek 021
MSF Access @msfaccess.org · 29/04/2026Neglected diseases are estimated to affect >1 billion people. However, there's limited attention and funding into vaccine research & development for these diseases. Safe & effective vaccines would be impactful in reducing the burden of neglected diseases. #WorldImmunisationWeek 031
MSF Access @msfaccess.org · 28/04/2026Each year, over a quarter of a million children acquire chronic hepatitis B at birth, resulting in many premature deaths. If every newborn received hepatitis B birth dose – an affordable vaccine supported by Gavi – these deaths could be prevented. #WorldImmunizationWeek 012
MSF Access @msfaccess.org · 27/04/2026Investing in innovations like vaccine Microarray Patches could help overcome barriers to reaching people in remote, conflict-affected, and fragile settings with vaccination. #WorldImmunisationWeek 032
MSF Access @msfaccess.org · 24/04/2026Tuberculosis continues to kill more than 1 million people each year. A safe, effective, and affordable vaccine to protect adolescents and adults against #tuberculosis would be a significant step towards reducing global mortality due to TB. #WorldImmunizationWeek 052
MSF Access @msfaccess.org · 21/04/2026At the WHO talks on pandemic agreement, MSF had been calling on the EU to engage constructively in a multilateral system that ensures equitable access to vaccines, diagnostics, and treatments for all. 000
MSF Access @msfaccess.org · 01/04/2026Before the diagnosis, Hareem and Ahmad were often unwell. They had poor appetite, abdominal pain, irritability, and were becoming weak. Their mother had taken them to a nearby clinic where they were given medicines without proper diagnosis, but their condition did not improve. 100
MSF Access @msfaccess.org · 31/03/2026The Head of the Paediatrics Department at Gujranwala Teaching Hospital (Pakistan), Dr Saima Umar, shares her experience of how WHO Treatment Decision Algorithms are helping diagnose children with #tuberculosis more effectively and the challenges doctors faced before their introduction. 000
MSF Access @msfaccess.org · 30/03/2026“The tools to diagnose and treat children with TB exist, even if imperfect, yet only half of the children who have TB are diagnosed or treated. For a truly global TB response, children must be prioritised now,” said Cathy Hewison, TB working group lead, MSF. 000
MSF Access @msfaccess.org · 26/03/2026“AMR in conflict or humanitarian settings is right there. It’s in front of us. We're already dealing with it.” Dr Kalyan Velivela, MSF health programme manager for South Sudan, Ethiopia, and Nigeria. Addressing AMR in humanitarian settings means acting on our shared experiences. 121
MSF Access @msfaccess.org · 06/03/2026The intellectual Property chapter of this trade deal largely preserves India’s public health safeguards and does not include any harmful provisions that go beyond the World Trade Organization’s TRIPS agreement, such as data exclusivity or patent term extensions. 110
MSF Access @msfaccess.org · 03/12/2025Yesterday, at Abrascão, Brazil's largest public health congress, MSF Access' Marcela Vieira explored how patent monopolies raise prices, limit access to health products, and deepen health inequities... and she shared a way to challenge them: www.patentoppositions.org 010
MSF Access @msfaccess.org · 28/11/2025On World Children’s Day (20 Nov 2025), TB activists and MSF marched in solidarity with children affected by tuberculosis at the Union World Conference on Lung Health in Copenhagen. To learn more about MSF’s work and engagement on TB in children, visit: www.msf.org/tactic-tuber... 095
MSF Access @msfaccess.org · 24/11/2025On #WorldAMRAwarenessWeek, we’re calling for concrete action to ensure access to existing diagnostic tools, microbiology capacities, legacy & new lifesaving antibiotics, and care for all... + an increase in R&D for low-resource & humanitarian settings, where it's most needed. 010
MSF Access @msfaccess.org · 20/11/2025We’re addressing AMR through dedicated prevention, detection, and response efforts across more than 20 countries, but there must be an increased global response. Improving access to microbiology labs 🔬 & lifesaving medicines 💊 in places with the greatest needs is essential. 041
MSF Access @msfaccess.org · 20/11/2025🦠 By 2050, AMR is estimated to contribute to 8.2 million deaths worldwide. For people living in fragile and conflict-affected settings, where access to infection prevention, diagnostics, and antimicrobials is limited, the impact of AMR is more severe. #WorldAMRAwarenessWeek 254
MSF Access @msfaccess.org · 14/11/2025Today is World Diabetes Day. More than 800 million people have diabetes, most of whom live in low- and middle-income countries. For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere. 110
MSF Access @msfaccess.org · 14/11/2025Lecritia, from South Africa, is comfortable using insulin pens. She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024). 100
MSF Access @msfaccess.org · 13/11/2025Scientists discovered insulin over 100 years ago, envisioning a world where everyone could access #diabetes treatment. But it is often unavailable or unaffordable. Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all. 001
MSF Access @msfaccess.org · 12/11/2025Today @who.int released their 2025 #tuberculosis report, and figures remain unacceptable: 1.2 million children and young adolescents fell ill in 2024, and a staggering 43% were never diagnosed and thus missed lifesaving treatment. Act now to close the deadly gap! msfaccess.org/msf-responds... 0510
MSF Access @msfaccess.org · 27/10/2025Every child withTB deserves a healthy childhood. Yet in 2023, 1.25M fell ill with TB and nearly half were never diagnosed, thus never treated. Join our webinar moderated by @johngreensbluesky.bsky.social where survivors and treatment providers will discuss how to close these deadly gaps. 1216
MSF Access @msfaccess.org · 24/10/2025🦠 It's estimated that by 2050, antibiotic resistance will cause 8.22 million deaths per year. To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses. Learn more: 100
MSF Access @msfaccess.org · 23/10/2025➡️ @saludporderecho.bsky.social reports that in Spain the public price of WHO recommended six-month treatment BPaLM regimen is priced at €58,000. In contrast, LMICs can access the same regimen for less than €250. saludporderecho.org/en/monopolie... 011
MSF Access @msfaccess.org · 15/10/2025Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic. 100
MSF Access @msfaccess.org · 15/10/2025At a panel discussion yesterday in Brussels, we urged policymakers, parliamentarians, regulatory agencies, and procurement bodies in the EU and the EEA to take urgent steps to bridge the gap in accessing tuberculosis treatment in the region. msfaccess.org/msf-urges-eu... 000
MSF Access @msfaccess.org · 13/10/2025⏰ Tomorrow! Don’t miss our panel on improving access to TB medicines in EU/EEA. People with TB still face barriers to effective treatment & prevention, let's discuss solutions. Register Now👉 us06web.zoom.us/webinar/regi... 011
MSF Access @msfaccess.org · 08/10/2025People with TB in EU and EEA still face limited access to effective treatment and prevention medicines. How can we fix that? On 14 Oct, join our panel discussion on how to improve the availability and affordability of TB medicines in the region. Register us06web.zoom.us/webinar/regi... 010
MSF Access @msfaccess.org · 24/09/2025More than 800 million people have diabetes, the majority of whom live in low- and middle-income countries. For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere. 264
MSF Access @msfaccess.org · 22/09/2025Fleeing home while managing #diabetes can mean losing reliable access to insulin which, in turn, risks severe health consequences, even death. Ghassan undertook a long, difficult journey with a limited supply of insulin. How did he manage his treatment? 🧵 100
MSF Access @msfaccess.org · 18/09/2025Sana was using continuous glucose monitoring (CGM) to monitor her blood sugar levels independently and discreetly. However, war disrupted her access to free CGMs, so she switched to finger-prick devices which she's less comfortable with. As a result, Sana monitors less often. 100
MSF Access @msfaccess.org · 17/09/2025“The main fear is just having those vials break.” Lecritia, from South Africa, is comfortable using insulin pens. She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024). 100
MSF Access @msfaccess.org · 12/09/2025In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine. In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations. 110
MSF Access @msfaccess.org · 12/09/2025In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine. In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations. 100
MSF Access @msfaccess.org · 13/08/2025Join us for a hybrid event at Tokyo International Conference on African Development #TICAD9 where we will discuss challenges & solutions for accessing diagnostics in Africa, feature MSF field innovations and explore collaborations with Japan. Register at www.msf.or.jp/event/detail... 000
MSF Access @msfaccess.org · 18/07/2025Lenacapavir has been recommended by @who.int for HIV prevention this week. While this prevention medicine could be a game-changer in turning the tide on HIV epidemic, Gilead's licensing agreement will undermine broad access. Here's why 👇 133
MSF Access @msfaccess.org · 13/06/2025Insulin pens must be affordable and available for all people with #diabetes who need them. Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes. 154
MSF Access @msfaccess.org · 12/06/2025Hey @novonordisk.bsky.social, all #insulin pens must be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit. 142
MSF Access @msfaccess.org · 15/05/2025📢 We are calling on donor agencies, governments, and philanthropic organisations to urgently step up to support people with #TB & #HIV. 0112
MSF Access @msfaccess.org · 15/05/2025As per @treatmentactiongroup.org and MSF’s analysis, TB trials that are at risk include new drugs and shorter, safer regimens for treatment and prevention, an optimised regimen for TB meningitis, and therapeutic and preventive vaccines. 1115
MSF Access @msfaccess.org · 15/05/2025Cutting support to sites in South Africa that are part of international clinical trial networks could derail up to 30% of global TB trial enrollment and between 50-90 % for studies focused on pediatric and pregnant populations. 1103
![“Gilead is paying lip service to equity and access while imposing restrictions on potential generic producers that will minimise scale-up of this game-changing [lenacapavir] drug while protecting and maximising its profits”, said Tom Ellman, Director of MSF Southern Africa Medical Unit.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:6vdu5tyfe5uprkloacu5pn6h/bafkreicd3n2c67ttucuirkreilcc2irj55v5qrah3qureygmshcotamyca)
